TOKYOMEDIJAPAN MEDICAL REFERENCE
⌕ Search databaseOfficial source · PMDA / MHLW
Rx · Reference only · no online purchase

Dupixent (Dupilumab)

Dupixent / Dupilumab. Used for selected inflammatory conditions such as atopic dermatitis and severe asthma, depending on formulation.

PMDAproduct-level source2026-03label updated2026-10-05site verified
デュピクセント皮下注300mg/200mg ペン・シリンジ · 300 mg / 2 mL
Japanese product photo · 300 mg / 2 mL · Lyall0 / CC BY-SA 4.0
Main useUsed for selected inflammatory conditions such as atopic dermatitis and severe asthma, depending on formulation.A brief overview of Japanese approved uses. Check the PMDA label below for product-specific conditions.
Japan product name
デュピクセント皮下注300mg/200mg ペン・シリンジ
Brand
Dupixent
Generic name
Dupilumab
Japanese generic name
デュピルマブ
Chinese name
度普利尤单抗
Marketing authorization holder
サノフィ株式会社
Strengths
200 mg / 300 mg
Dosage form
SC pen / syringe
Therapeutic area
Immunology
Regulatory status
Rx
Label updated
2026-03
TOKYO MEDI verified
2026-10-05
MEDICINE REFERENCE

Detailed product reference

Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.

01

Product overview

Dupixent is an IL-4-receptor-alpha antibody with Japanese 200/300 mg syringe and pen presentations.

Read source section ↗
02

Mechanism of action

Blocks IL-4/IL-13 signaling involved in type-2 inflammation; it is not an acute asthma reliever.

Read source section ↗
03

Japanese indications & eligibility

Uses vary by formulation and include selected dermatitis, urticaria, asthma and additional 300 mg indications.

Read source section ↗
04

Administration & dose differences

Some adult regimens load 600 mg then 300 mg every two weeks; pediatric and other indication schedules differ.

Read source section ↗
05

Adverse effects & key risks

Watch injection reactions, ocular inflammation, hypersensitivity and eosinophilic conditions.

Read source section ↗
06

Contraindications & special populations

Ingredient hypersensitivity is contraindicated; assess helminth infection, vaccination and other treatment changes.

Read source section ↗
07

Drug interactions

Review live vaccines and clinician-supervised steroid/combination therapy changes.

Read source section ↗
08

Assessment & monitoring

Follow disease control, ocular symptoms and injection technique; verify handling and disposal training.

Read source section ↗
09

Storage & handling

Refrigerate at 2–8°C; once removed, keep boxed ≤25°C and use within 14 days. Do not freeze, shake or heat.

Read source section ↗
10

Sources & verification

Product checked ·

Official source

These links go directly to PMDA records for this Japanese product. Professional and patient-facing sources are separated.